07:55 AM EDT, 10/13/2025 (MT Newswires) -- AstraZeneca ( AZN ) said Friday it reached an agreement with the Trump administration to reduce the cost of prescription medicines for patients.

The move will help patients access drugs at prices that are "equalized with those available in wealthy countries," the company said.

As part of the deal, AstraZeneca ( AZN ) will provide direct-to-consumer sales to eligible patients with prescriptions for chronic diseases at a discount of as much as 80% off list prices. The company will participate in the TrumpRx.gov platform, allowing users to buy medicines at a reduced cash price.

AstraZeneca ( AZN ) also said it struck a deal with the US Department of Commerce to delay sector-specific tariffs for three years.

The company plans a $50 billion investment in US drug manufacturing and research and development over the next five years to help deliver $80 billion in revenue by 2030, 50% of which is expected to be generated in the US, it said.